Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perflenapent - NuvOX Pharma

Drug Profile

Perflenapent - NuvOX Pharma

Alternative Names: DDFPe; Dodecafluoropentane; NanO2; NVX 208; NVX-108; Perfluoropentane; PFP

Latest Information Update: 07 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NuvOx Pharma
  • Class Anti-ischaemics; Antianaemics; Antihaemorrhagics; Antineoplastics; Fluorocarbons; Neuroprotectants; Radiation-sensitising agents; Radiosensitisers; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Stroke
  • Preclinical Haemorrhagic shock; Myocardial infarction; SARS-CoV-2 acute respiratory disease; Sickle cell anaemia; Traumatic brain injuries; Triple negative breast cancer

Most Recent Events

  • 31 Mar 2023 Phase-II clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, First-line therapy) in USA (IV) (NCT03862430)
  • 02 Mar 2023 NuvOx Pharma has patent protection for Perflenapent in USA
  • 02 Mar 2023 Adverse events and pharmacodynamics data from preclinical studies in Stroke released by NuvOx Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top